Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQGZ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,158
Award facts
- Contract value 100% obligated
- $3,158.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,158.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for XOLAIR 150 mg/ml syringes. The award, issued on February 4, 2026, with an ultimate completion date of February 26, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply comprehensive pharmaceutical products to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in 2001. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. Under the parent PPV-G GEN V contract designated SPE2DR, with a ceiling value of $499,999,999 and completion date of December 31, 2036, DMS Pharmaceutical Group serves as a regional prime vendor contractor positioned to fulfill diverse and specialized pharmaceutical requirements across the military medical system globally. This delivery order for XOLAIR, an immunosuppressant biologic agent, exemplifies the company's role in supporting recurring medical supply needs of DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQGZ1?
SPE2DR26FQGZ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FQGZ1 worth?
The government has obligated $3,158 on SPE2DR26FQGZ1.
Is contract SPE2DR26FQGZ1 an order under another contract?
Yes. SPE2DR26FQGZ1 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGZ1 competed?
The extent of competition for SPE2DR26FQGZ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award